Abstract
Clinicians treating patients with antiphospholipid syndrome or antiphospholipid antibodies must often make treatment decisions based on relatively weak evidence. Antiphospholipid syndrome is diagnosed in patients who have persistent antiphospholipid antibodies with clinical manifestations, such as pregnancy complications, thrombotic manifestations, or both.1 In light of the various clinical manifestations, the design and conduct of randomised controlled trials to inform the optimal management of patients with antiphospholipid syndrome remains difficult.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
